| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530386000 |
Globulins
| 1510 |
| 530381000 |
Blood coagulation factors and fibrin, e.g., thromboplastin, etc.
| 68 |
| 530385000 |
Hemoglobins or globins | 4 |
| 20120004396 | COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics. | 01-05-2012 |
| 20130217860 | METHODS FOR PREPARING PEG-HEMOGLOBIN CONJUGATES USING REDUCED REACTANT RATIOS - The present invention relates generally to methods for preparing polyethylene glycol (“PEG”) conjugated hemoglobin (“Hb”) using reduced reactant ratios. More specifically, the present invention relates to methods for preparing PEG conjugated Hb (“PEG-Hb”) with enhanced yield and purity. | 08-22-2013 |
| 20110071275 | Compositions and methods of use of neurovascular protective multifunctional polynitroxylated pegylated carboxy hemoglobins for transfusion and critical care medicine - The present invention describes novel neuroprotective and multifunctional intra- and inter-molecular redox coupled polynitroxylated pegylated carboxy hemoglobins as high therapeutic index agents for un-met medical needs or diseases, which require acute or chronic alleviation of oxidative stress and correction of inadequate blood flow resulting from physical injury, ischemia, reperfusion injury, and inflammation injury in either or both pre-hospital and in-hospital transfusion and critical care medicine. These hemoglobins are triple-modified with a focus on therapeutic activities rather than oxygen carrying ability. | 03-24-2011 |
| 20120059153 | METHODS FOR PREPARING STABLE DEOXYGENATED PEG-HEMOGLOBIN CONJUGATE SOLUTIONS COMPRISING AN ANTIOXIDANT - The present invention is a method for preparing stable HBOC solutions. Specifically, the method comprises the steps of deoxygenating a PEG-Hb conjugate and adding one or more antioxidants during or following the deoxygenating step to form a stabilized PEG-Hb conjugate. The Hb in the PEG-Hb conjugate is not crosslinked and the stabilized PEG-Hb conjugate has a p50 less than that of native SFH from the same animal source when measured under the same conditions. Specifically, the p50 is 6±2 mmHg or less than 10 mmHg. | 03-08-2012 |
| Entries |
| Document | Title | Date |
|---|
| 20150065689 | SINGLE STEP FRACTIONATION METHOD - Single step method of enriching highly sialylated variant/s of a protein by use of a strong ion exchange chromatography support and a pH gradient in absence of any salt gradient. | 03-05-2015 |
| 20150045538 | MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA - The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction. | 02-12-2015 |
| 20100160610 | Conjugates of an EPO Moiety and a Polymer - Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient. | 06-24-2010 |
| 20140296487 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses - Modified human plasma polypeptides or Fc and uses thereof are provided. | 10-02-2014 |
| 20140275484 | METHOD FOR PRODUCING FACTOR H FROM A PLASMA PRECIPITATION FRACTION - The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein. | 09-18-2014 |
| 20120220757 | NOVEL CARBAMYLATED EPO AND METHOD FOR ITS PRODUCTION - The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof. | 08-30-2012 |
| 20100081791 | GLYCOPEGYLATED FACTOR IX - The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates. | 04-01-2010 |
| 20090247734 | Chemically Derivatized CD4 and Uses Thereof - This invention provides two soluble polypeptides which comprise a portion of CD4 comprising all HIV gp120-binding epitopes present on intact CD4, wherein the polypeptide has a cysteine substitution at a residue which, in intact CD4, interfaces with HIV gp120. This invention also provides a method for making a derivatized soluble polypeptide and a method for obtaining a structural model useful in the design of an agent for inhibiting CD4 binding to HIV gp120. | 10-01-2009 |
| 20130303731 | MANUFACTURE OF FACTOR H (FH) AND FH-DERIVATIVES FROM PLASMA - The present invention provides compositions and pharmaceutical formulations of Factor H derived from plasma. Also provided are methods for the manufacture of the Factor H compositions and formulations, as well as methods for the treatment of diseases associated with Factor H dysfunction. | 11-14-2013 |
| 20130131317 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 05-23-2013 |
| 20140088294 | PRODUCTION OF GLYCOPROTEINS USING MANGANESE - Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided. | 03-27-2014 |
| 20140163207 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN - Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange SP Sephacryl™ S 500 HR chromatography material conditioned to a conductivity of 21 mS/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield. | 06-12-2014 |
| 20120197007 | METHOD FOR PURIFYING PEGylated ERYTHROPOIETIN - Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly(ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange SP Sephacryl™ S 500 HR chromatography material conditioned to a conductivity of 21 mS/cm and a linear gradient elution a fusion protein of erythropoietin and a single poly(ethylene glycol) residue can be obtained in a single step with high purity and yield. | 08-02-2012 |
| 20090054629 | Inhibitors of Transthyretin Amyloid Fibril Formation - Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin. | 02-26-2009 |
